Zoetis (ZTS) : Analyst Rating Update

Zoetis (ZTS) has an average broker rating of 1.8, which is interpreted as a Buy, as rated by 10 equity analysts. Nonetheless, 6 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 1, which is also a Strong Buy.

Zoetis (ZTS) : The most positive equity analysts on Zoetis (ZTS) expects the shares to touch $62, whereas, the least positive believes that the stock will trade at $45 in the short term. The company is covered by 8 Wall Street Brokerage Firms. The average price target for shares are $53.13 with an expected fluctuation of $5.72 from the mean.

Zoetis (NYSE:ZTS): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $47.21 and $47.01 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $48.14. The buying momentum continued till the end and the stock did not give up its gains. It closed at $48.09, notching a gain of 1.24% for the day. The total traded volume was 3,451,627 . The stock had closed at $47.50 on the previous day.

Also, Equity Analysts at the Jefferies maintains the rating on Zoetis (NYSE:ZTS). The brokerage firm has issued a Buy rating on the shares. The Analysts at the ratings agency raises the price target from $57 per share to $58 per share. The rating by the firm was issued on June 14, 2016. The company shares have rallied 2.19% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $50.39 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $47.23 and the 200 Day Moving Average price is recorded at $45.12.

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses, and five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.